Results 51 to 60 of about 41,377 (182)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients

open access: yesAnnals of Hepatology, 2019
Introduction and aim. We assessed the characteristics of virological response to a combination treatment of ombitasvir, paritaprevir, and ritonavir in hepatitis C virus genotype 1-infected elderly Japanese patients.Material and Methods.
Haruki Uojima   +11 more
doaj   +1 more source

Is Hypercortisolism Treatable? Which Patients Should Be Treated and How—A Practical Guide for Clinicians

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To provide a practical guide on when to suspect endogenous hypercortisolism, how to use the overnight 1‐mg dexamethasone suppression test (DST) for targeted case‐finding, and which patients are most likely to benefit from treatment.
Juan Pablo Frias
wiley   +1 more source

Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID‐19

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Introduction Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Ruben Jara Rubio   +38 more
wiley   +1 more source

Antiviral therapy of chronic hepatitis C complicated by systemic cryoglobulinemic vasculitis

open access: yesЖурнал инфектологии, 2016
Literature analysis of published data on mechanisms of infection, disease progression and treatment of chronic hepatitis C, associated with systemic cryoglobulinemic vasculitis and kidney involvement is presented.
N. V. Dunaeva   +6 more
doaj  

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All‐Cause Mortality After SVR in Advanced Chronic Hepatitis C

open access: yesHepatology Research, EarlyView.
ABSTRACT Background and Aims Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA).
Daisuke Sakon   +19 more
wiley   +1 more source

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

open access: yesBMC Infectious Diseases, 2003
Background Low-dose ritonavir (RTV) boosts plasma amprenavir (APV) exposure. Little has been published on the efficacy, tolerability, and safety of APV 600 mg/RTV 100 mg (APV600/RTV) twice daily (BID) compared to APV 1200 mg BID (APV1200).
Griffith Sandy   +8 more
doaj   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani   +7 more
wiley   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

open access: yesHIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy